MOG Antibody-Associated Disease (MOGAD) Clinical Trials

Myelin is the insulating coat that lets nerve signals travel quickly. Myelin oligodendrocyte glycoprotein, or MOG, is a protein on the outer surface of that coat in the brain, spinal cord and optic nerves. In MOGAD the immune system makes antibodies against MOG and inflammation strips the myelin where they bind.

The most common symptoms of MOG Antibody-Associated Disease include Blurred or lost vision in one or both eyes, usually with pain on eye movement (optic neuritis), Loss of color vision, Weakness or paralysis in the legs or arms from spinal cord inflammation (transverse myelitis), Numbness or loss of sensation, Bladder or bowel problems, including being unable to empty the bladder, among others. Roughly 0.5 to 3.4 people per 100,000 (Genentech); the MOG antibody is found in 40% to 58% of children with ADEM and in 7.4% to 39% of people with NMOSD who test negative for the aquaporin-4 antibody. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for MOG Antibody-Associated Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. There is no FDA-approved treatment for MOGAD as of October 2026, and the first could arrive in January. Enspryng (satralizumab), Genentech's monthly under-the-skin injection that blocks the interleukin-6 receptor, is approved for aquaporin-4 NMOSD and was tested in MOGAD in the Phase 3 METEOROID trial (NCT05271409) in adults and adolescents 12 and older, who could stay on their existing preventive medicine during the study.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to MOG Antibody-Associated Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

MOG Antibody-Associated Disease is an acquired condition, not an inherited one. MOGAD is an autoimmune disease, not an inherited one; the diagnostic test is a blood test for the MOG antibody, not a genetic test. Roughly 0.5 to 3.4 people per 100,000 (Genentech); the MOG antibody is found in 40% to 58% of children with ADEM and in 7.4% to 39% of people with NMOSD who test negative for the aquaporin-4 antibody.

Eligibility for MOG Antibody-Associated Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a MOG Antibody-Associated Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.